TY - JOUR
T1 - Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
AU - Alam, Manzar
AU - Hasan, Gulam Mustafa
AU - Eldin, Sayed M.
AU - Adnan, Mohd
AU - Riyaz, Muhammad Bilal
AU - Islam, Asimul
AU - Khan, Ilyas
AU - Hassan, Md Imtaiyaz
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/5
Y1 - 2023/5
N2 - Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The signaling cascades are stimulated via genetic modifications in upstream signaling molecules, which affect apoptotic, proliferative, and differentiation pathways. Dysregulation of these signaling cascades causes cancer-initiating cell proliferation, cancer development, and drug resistance. Numerous efforts in the treatment of NSCLC have been undertaken in the past few decades, enhancing our understanding of the mechanisms of cancer development and moving forward to develop effective therapeutic approaches. Modifications of transcription factors and connected pathways are utilized to develop new treatment options for NSCLC. Developing designed inhibitors targeting specific cellular signaling pathways in tumor progression has been recommended for the therapeutic management of NSCLC. This comprehensive review provided deeper mechanistic insights into the molecular mechanism of action of various signaling molecules and their targeting in the clinical management of NSCLC.
AB - Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The signaling cascades are stimulated via genetic modifications in upstream signaling molecules, which affect apoptotic, proliferative, and differentiation pathways. Dysregulation of these signaling cascades causes cancer-initiating cell proliferation, cancer development, and drug resistance. Numerous efforts in the treatment of NSCLC have been undertaken in the past few decades, enhancing our understanding of the mechanisms of cancer development and moving forward to develop effective therapeutic approaches. Modifications of transcription factors and connected pathways are utilized to develop new treatment options for NSCLC. Developing designed inhibitors targeting specific cellular signaling pathways in tumor progression has been recommended for the therapeutic management of NSCLC. This comprehensive review provided deeper mechanistic insights into the molecular mechanism of action of various signaling molecules and their targeting in the clinical management of NSCLC.
KW - Apoptosis
KW - Cancer signaling
KW - Non-small cell lung carcinoma
KW - Small molecule inhibitors
KW - Targeted therapy, Drug development
UR - http://www.scopus.com/inward/record.url?scp=85149323949&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2023.114452
DO - 10.1016/j.biopha.2023.114452
M3 - Review article
C2 - 36878052
AN - SCOPUS:85149323949
SN - 0753-3322
VL - 161
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
M1 - 114452
ER -
